Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, has scheduled a webcast for May 14, 2025, at 4:30 p.m. Eastern Time. During the webcast, the company will discuss its financial results for the first quarter ended March 31, 2025, and provide a business update.

The webcast will be accessible through the company's investor relations website, and a replay will be available for approximately 90 days following the event. Belite Bio specializes in developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.

News Market Reaction

+0.36%

1 alert

+0.36% News Effect

On the day this news was published, BLTE gained 0.36%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2025.

Webcast Information
Date: Wednesday, May 14, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/137642555

Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

When is Belite Bio (BLTE) hosting its Q1 2025 earnings webcast?

Belite Bio will host its Q1 2025 earnings webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

How can I access Belite Bio's Q1 2025 earnings webcast?

The webcast can be accessed through https://events.q4inc.com/attendee/137642555 or through the 'Presentations & Events' section of Belite Bio's Investor Relations website at https://investors.belitebio.com/presentations-events/events.

How long will the replay of Belite Bio's Q1 2025 earnings webcast be available?

A replay of the webcast will be available for approximately 90 days after the event.

What is Belite Bio's main business focus?

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs.